

# 2022 Annual Meeting of the Section of Pediatric Neurological Surgery

December 1-4, 2022 Washington, D.C.

# RELEVANT CONFLICT OF INTEREST DISCLOSURES AND EDUCATIONAL GRANTS

#### ACCREDITATION

#### **ACCME Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Congress of Neurological Surgeons and the AANS/CNS Section on Pediatric Neurological Surgery. The Congress of Neurological Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

## AMA Credit Designation Statement(s)

The CNS designates this live activity for a maximum of 24.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **NON-CME SESSIONS**

Per the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all NON-CME sessions at the 2022 Annual Meeting of the Section of Pediatric Neurological Surgery will be held in a separate room from accredited continuing education.

#### RELEVANT CONFLICT OF INTEREST DISCLOSURES

#### **CNS Disclosure Policy**

The Congress of Neurological Surgeons controls the content and production of this CME activity and attempts to assure the presentation of balanced, objective information. In accordance with the Standards for Integrity and Independence in Accredited Continuing Education established by the Accreditation Council for Continuing Medical Education (ACCME), speakers are asked to disclose all relationships they have with ineligible companies\* over the previous 24 months which may be related to the content of their lecture. Speakers who have disclosed a relationship with an ineligible company whose products may have a relevance to their presentation are listed below.

# Any planner, reviewer, or faculty member not on the disclosure list has reported they have nothing to disclose.

All relevant financial relationships listed for these individuals have been mitigated.

Agenda and faculty subject to change

#### Reviewers

| Individual's Name | Name(s) of Ineligible Company | Nature of Relationship(s) |
|-------------------|-------------------------------|---------------------------|
| Tiffany Hodges    |                               | Nothing to Disclose       |
| Akash Patel       |                               | Nothing to Disclose       |

#### **Planners**

| Individual's Name     | Name(s) of Ineligible Company              | Nature of<br>Relationship(s) |  |
|-----------------------|--|------------------------------|--|
| Todd C. Hankinson     | Monteris Medical, Inc.                     | Consulting Fee               |  |
| Jeffrey R. Leonard    | Hyperfine, Inc.                            | Contracted Research          |  |
| Carrie R. Muh         | LivaNova, LLC                              | Speakers Bureau              |  |
| Robert Partlow Naftel | Zimmer/Biomet                              | Consulting Fee               |  |
| Matthew D. Smyth      | Monteris Medical, Inc., Zimmer Biomet ROSA | Consulting Fee               |  |

### **Faculty**

| Individual's Name   | Name(s) of Ineligible Company | Nature of Relationship(s) |  |
|---------------------|-------------------------------|---------------------------|--|
| Samuel Robert Browd | Propriovision, Inc.           | Consulting Fee            |  |
|                     |                               | Receipt of IP             |  |
| P. David Adelson    | Medtronic, Inc.               | Speakers Bureau           |  |
| Samer K. Elbabaa    | KARL STORZ Endoskope          | Speakers Bureau           |  |
| Jeffrey R. Leonard  | Hyperfine, Inc.               | Contracted Research       |  |
| Ian F. Pollack      | Cothera Bioscience            | Recipt of IP              |  |

<sup>\*</sup>Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. An ineligible company is not eligible for ACCME accreditation or participation in Joint Providership.

| Individual's Name | Name(s) of Ineligible Company        | Nature of Relationship(s) |  |
|-------------------|--------------------------------------|---------------------------|--|
| Matthew D. Smyth  | Monteris Medical, Zimmer Biomet ROSA | Consulting Fee            |  |
| Marion L. Walker  | Medtronic, Inc.                      | Consulting Fee            |  |

## **EDUCATION GRANTS & IN-KIND EQUIPMENT**

#### **Commercial Support:**

Congress of Neurological Surgeons wishes to recognize and thank the following for providing an educational grant and/or use of equipment (in-kind):

| Name of Commercial Supporter | In-Kind Support | Financial Support |
|------------------------------|-----------------|-------------------|
| Ace Medical Co.              | No              | Yes               |
| Aesculap, Inc.               | No              | Yes               |
| BK Medical                   | No              | Yes               |